Ashurst advises APONTIS PHARMA on the conclusion of an investor agreement with Zentiva and the intended voluntary purchase offer by Zentiva to all shareholders of APONTIS PHARMA.
On 16 October 2024, APONTIS PHARMA announced the conclusion of an investor agreement with Zentiva Pharma GmbH and Zentiva AG, which aims to support the future growth of APONTIS PHARMA through Zentiva. Zentiva AG will make a voluntary public purchase offer for all outstanding shares of APONTIS PHARMA at an offer price of EUR 10.00 per share in cash.
APONTIS PHARMA AG is a leading pharmaceutical company in Germany specialising in single-pill combinations. Single-pill combinations combine two to three off-patent active ingredients in a single-pill product taken once a day. Scientifically supported, single-pill therapies significantly improve the treatment prognosis and quality of life of patients, while reducing complications, mortality and treatment costs.
The Ashurst team was led by counsel Martina Rothe and partner Dr Stephan Hennrich and included associate Benedikt Lerp (all corporate, all Frankfurt).
